News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
The diagnostics and research group’s weekly context shows a sustained rebound, though the trend screen has not yet moved to active.
Thermo Fisher Scientific Inc. TMO raised its 2026 outlook after second-quarter earnings and revenues exceeded expectations. The update reflects stronger customer activity, better acquisition performance and improved operating leverage. The key question is whether the higher forecast marks a durable recovery across end markets …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Thermo Fisher Scientific (TMO) is back in focus after reporting second quarter results that exceeded market expectations, supported by broad-based demand and fresh regulatory clearances …
The Top 5 Analyst Questions From Thermo Fisher's Q2 Earnings Call Thermo Fisher's second quarter saw a notable uptick in end-market activity, propelling results above Wall Street's expectations and leading to a positive market reaction. Management pointed to stronger demand across pharmaceutical, biotech, industrial, …
The diagnostics and research supplier is extending a three-month advance, though the trend screen has not turned active.
Thermo Fisher Scientific Inc.'s President & COO, Gianluca Pettiti, sold 400 shares of common stock for $565.00 per share on July 27, 2026. This transaction, totaling $226,000, was conducted under a Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Pettiti directly …
Sharemaestro market context Trend signal started 52 weeks +18.1%Thermo Fisher Scientific (TMO) stock increased by 3.20% due to strong quarterly earnings that surpassed estimates and an increased full-year organic revenue growth forecast. The company benefits from rising biopharma spending, demand for clinical services, and increased capital expenditure from pharmaceutical clients. Technical indicators …
Analysts have raised the 12-month average price target for Thermo Fisher Scientific Inc (TMO) stock to $634.92, up from $629.92, implying a 13% potential upside based on the July 27 closing price. The consensus rating from 30 analysts remains a "Buy," with 25 recommending …
Shares of Thermo Fisher Scientific Inc. (TMO) rose 3.02% to $576.41 on Tuesday, outperforming the broader market. The S&P 500 Index increased by 0.21% and the Dow Jones Industrial Average rose by 1.03% on the same day. This rise ended a two-day losing streak …
Sharemaestro market context Trend signal started 52 weeks +13.8%An insider at Thermo Fisher Scientific Inc. (NYSE: TMO) plans to sell 400 shares of common stock, valued at $226,000.00, through Fidelity Brokerage Services LLC. These shares originate from restricted stock vesting awards received as compensation in February 2024. The filing also notes that …
Thermo Fisher Scientific has launched the new Thermo Scientific InstaFlux workflow, an integrated media preparation and sample enrichment system designed to enhance productivity, simplify pathogen testing, and boost traceability for food microbiology laboratories. This on-demand system allows laboratories to prepare enrichment media in under …
Thermo Fisher Scientific is showcasing its latest diagnostic innovations and solutions at the Association of Diagnostics & Laboratory Medicine Conference (ADLM) 2026. The company highlights its end-to-end diagnostic and lab solutions, including advancements in multiple myeloma monitoring, oncology testing, critical care, and autoimmune diagnostics. …
The global Flow Cytometry Diagnostics Market is projected to grow from USD 1.5 billion in 2026 to USD 3.5 billion by 2036, at an 8.9% CAGR, driven by rising demand for hematologic malignancy testing, MRD monitoring, and immunophenotyping. Flow Cytometers lead product demand with …
Thermo Fisher Scientific only hired about a third of the 500+ employees it pledged for a regional expansion project announced in 2022, leading to the company receiving only a fraction of the potential $5.4 million in incentives. While capital investment goals were met, the …
Shares of Thermo Fisher Scientific Inc. (TMO) fell by 1.54% on Monday, closing at $559.53. This decline occurred despite a positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains. This marks the second …
This article details the shareholder structure of Thermo Fisher Scientific Inc (TMO), listing major shareholders like Vanguard Capital Management and BlackRock Institutional Trust Company. It also provides a breakdown of shareholder types, institutional holdings over recent quarters, and significant changes in shareholding by various …
Thermo Fisher Scientific Inc. insider Gianluca Pettiti has filed to sell 400 shares of common stock through Fidelity Brokerage Services LLC, with an indicated value of $226,000. This filing is a Form 144, which is a notice of a proposed sale of securities, and …
Sharemaestro market context Trend signal started 52 weeks +18.1%Piper Sandler has increased its price target for Thermo Fisher Scientific (NYSE: TMO) to $600 from $510, while maintaining a Neutral rating on the stock. This adjustment comes after the company's strong Q2 performance, though RBC notes it may not 'meaningfully' change the H2 …
Thermo Fisher Scientific's stock rose 6.7% after reporting strong Q2 2026 results, including US$11.99 billion in sales and US$1.74 billion in net income. The company also completed a US$4.00 billion share repurchase program and launched InstaFlux, an innovative workflow for food microbiology labs. These …
Sharemaestro market context Trend signal active 52 weeks +39.2% · Next-week setup positive 55.1%Thermo Fisher Scientific (TMO) recently reported Q2 2026 results with revenue of US$12.0 billion and EPS of US$4.68, showing growth in earnings but a slight slip in net profit margins from 15.2% to 15%. This margin stagnation, coupled with a high debt load of …
Morgan Stanley has increased its price target for Thermo Fisher (TMO) to $650 from $620, while maintaining an Overweight rating. This adjustment follows the company's strong Q2 results, with improved visibility into strengthening end markets. The firm also factored in the anticipated microbiology divestiture …
Thermo Fisher Scientific's (TMO) broad-based improvement in Q2 is not enough to "meaningfully" chang PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …
Thermo Fisher Scientific has launched its new GENESYS G5 series of visible and UV-visible spectrophotometers, featuring three configurations (Vis, UV-Vis, UV-Vis Pro) built around a common software platform. This suite is designed to help laboratories standardize workflows and incrementally expand analytical capabilities across various …
TMO Q2 Deep Dive: Broad-Based End Market Growth and Strategic Portfolio Moves Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per …
This article discusses the critical role of connected laboratory data in advancing scientific discovery, automation, and artificial intelligence. David Hardy from Thermo Fisher Scientific explains how addressing fragmented data, implementing connected workflows, and establishing robust data governance are essential for laboratories to leverage AI …
Wells Fargo has increased its price target for Thermo Fisher Scientific (TMO) to $660 from $615, while maintaining an "Overweight" rating on the stock. This adjustment reflects continued confidence from the bank in the scientific instrument and service company's performance. The article also lists …
Search by ticker symbol or company name and select a result to open its chart. The US only control limits results to active US-listed stocks and ETFs.
Showing active US-listed stocks and ETFs only.